Literature DB >> 2498205

Complement activation and C3 binding by serum-sensitive and serum-resistant strains of Pseudomonas aeruginosa.

N L Schiller1, R A Hatch, K A Joiner.   

Abstract

The relationship among complement consumption, C3 deposition, and C3 fragmentation pattern was compared for serum-sensitive (Sers) and serum-resistant (Serr) strains of Pseudomonas aeruginosa. The Sers strains, which were mucoid strains derived from patients with cystic fibrosis, had lipopolysaccharide deficient in O-antigen side chains. These organisms generally activated much less complement per organism than their Serr counterparts, characterized by the presence of lipopolysaccharide with long lipopolysaccharide O side chains. Surprisingly, however, although the Serr strains consumed more total hemolytic complement, less C3 was deposited onto the surface of these strains than onto that of the Sers strains. Maximal C3 binding required the participation of both the classical and alternative complement pathways, although classical complement pathway involvement was more important for Serr strains. Finally, while more than half of the C3 deposited on most Sers strains was in the form of C3b, most of the C3 on the Serr strains was in the form of iC3b, indicating a more rapid and extensive conversion of C3b to iC3b on the surface of these strains. Limited complement activation by Sers mucoid strains of P. aeruginosa may confer a selective survival advantage to these organisms in colonizing the airways of patients with cystic fibrosis.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2498205      PMCID: PMC313344          DOI: 10.1128/iai.57.6.1707-1713.1989

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  31 in total

1.  Interaction between the third complement protein and cell surface macromolecules.

Authors:  S K Law; R P Levine
Journal:  Proc Natl Acad Sci U S A       Date:  1977-07       Impact factor: 11.205

2.  Activation of the classical and properdin pathways of complement by bacterial lipopolysaccharides (LPS).

Authors:  D C Morrison; L F Kline
Journal:  J Immunol       Date:  1977-01       Impact factor: 5.422

3.  Pseudomonas aeruginosa isolates from patients with cystic fibrosis: a class of serum-sensitive, nontypable strains deficient in lipopolysaccharide O side chains.

Authors:  R E Hancock; L M Mutharia; L Chan; R P Darveau; D P Speert; G B Pier
Journal:  Infect Immun       Date:  1983-10       Impact factor: 3.441

4.  Complement activation via the alternative pathway by purified Salmonella lipopolysaccharide is affected by its structure but not its O-antigen length.

Authors:  N Grossman; L Leive
Journal:  J Immunol       Date:  1984-01       Impact factor: 5.422

5.  Large scale isolation of functionally active components of the human complement system.

Authors:  C H Hammer; G H Wirtz; L Renfer; H D Gresham; B F Tack
Journal:  J Biol Chem       Date:  1981-04-25       Impact factor: 5.157

6.  Complement activation by polysaccharide of lipopolysaccharide: an important virulence determinant of salmonellae.

Authors:  C J Liang-Takasaki; H Saxén; P H Mäkelä; L Leive
Journal:  Infect Immun       Date:  1983-08       Impact factor: 3.441

Review 7.  Infections caused by Pseudomonas aeruginosa.

Authors:  G P Bodey; R Bolivar; V Fainstein; L Jadeja
Journal:  Rev Infect Dis       Date:  1983 Mar-Apr

8.  The relationship of phenotype changes in Pseudomonas aeruginosa to the clinical condition of patients with cystic fibrosis.

Authors:  A Penketh; T Pitt; D Roberts; M E Hodson; J C Batten
Journal:  Am Rev Respir Dis       Date:  1983-05

9.  Identification of the membrane glycoprotein that is the C3b receptor of the human erythrocyte, polymorphonuclear leukocyte, B lymphocyte, and monocyte.

Authors:  D T Fearon
Journal:  J Exp Med       Date:  1980-07-01       Impact factor: 14.307

10.  Studies on the mechanism of bacterial resistance to complement-mediated killing. I. Terminal complement components are deposited and released from Salmonella minnesota S218 without causing bacterial death.

Authors:  K A Joiner; C H Hammer; E J Brown; R J Cole; M M Frank
Journal:  J Exp Med       Date:  1982-03-01       Impact factor: 14.307

View more
  14 in total

1.  Clearance of Bordetella parapertussis from the lower respiratory tract requires humoral and cellular immunity.

Authors:  Daniel N Wolfe; Girish S Kirimanjeswara; Eric T Harvill
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

2.  Phenotypic conversion of Pseudomonas aeruginosa in cystic fibrosis.

Authors:  M Fegan; P Francis; A C Hayward; G H Davis; J A Fuerst
Journal:  J Clin Microbiol       Date:  1990-06       Impact factor: 5.948

Review 3.  Complement resistance in microbes.

Authors:  M C Moffitt; M M Frank
Journal:  Springer Semin Immunopathol       Date:  1994

4.  Legionella pneumophila lipopolysaccharide activates the classical complement pathway.

Authors:  C S Mintz; D R Schultz; P I Arnold; W Johnson
Journal:  Infect Immun       Date:  1992-07       Impact factor: 3.441

5.  O antigen protects Bordetella parapertussis from complement.

Authors:  Elizabeth M Goebel; Daniel N Wolfe; Kelly Elder; Scott Stibitz; Eric T Harvill
Journal:  Infect Immun       Date:  2008-02-19       Impact factor: 3.441

6.  Analysis of acquisition of Pseudomonas aeruginosa gastrointestinal mucosal colonization and horizontal transmission in a murine model.

Authors:  Akinobu Kamei; Andrew Y Koh; Mihaela Gadjeva; Gregory P Priebe; Stephen Lory; Gerald B Pier
Journal:  J Infect Dis       Date:  2010-01-01       Impact factor: 5.226

7.  Specificity of the thioester-containing reactive site of human C3 and its significance to complement activation.

Authors:  A Sahu; T R Kozel; M K Pangburn
Journal:  Biochem J       Date:  1994-09-01       Impact factor: 3.857

Review 8.  Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia.

Authors:  J R Govan; V Deretic
Journal:  Microbiol Rev       Date:  1996-09

9.  Pseudomonas aeruginosa variants isolated from patients with cystic fibrosis are killed by a bactericidal protein from human polymorphonuclear leukocytes.

Authors:  C M Siefferman; W E Regelmann; B H Gray
Journal:  Infect Immun       Date:  1991-06       Impact factor: 3.441

10.  The anti-lipid A monoclonal antibody E5 binds to rough gram-negative bacteria, fixes C3, and facilitates binding of bacterial immune complexes to both erythrocytes and monocytes.

Authors:  M A Seelen; P Athanassiou; W A Lynn; P Norsworthy; M J Walport; J Cohen; K A Davies
Journal:  Immunology       Date:  1995-04       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.